Lilly reports $24.4 billion in third-quarter revenue and raises 2026 guidance
Lilly’s third-quarter revenue rose 39% to $24.4 billion as volume increased 53% and realized prices fell 15%. Management raised full-year revenue guidance to $91 billion–$92 billion and adjusted EPS guidance to $35–$36. Mounjaro and Zepbound drove demand, while lower realized prices partly offset volume growth. About $900 million in one-time benefits supported the quarter.
Lilly agrees to acquire Calytrix Bio for up to $1.5 billion
Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion, including upfront cash and milestone payments. Calytrix is developing an early-stage antibody targeting mutant calreticulin in essential thrombocythemia and myelofibrosis. The acquisition would expand Lilly’s blood cancer pipeline beyond diabetes and obesity treatments, but the candidate still needs clinical testing.
Health Canada approves Mounjaro to reduce cardiovascular risk
Health Canada approved Eli Lilly’s Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The decision was based on SURPASS-CVOT, a trial of more than 13,000 participants in which Mounjaro was non-inferior to Trulicity, with an estimated 8% lower rate of cardiovascular death, heart attack, or stroke. Reported adverse events were consistent with its established safety profile.
Lilly presents obesity and cardiometabolic trial data at ObesityWeek
Eli Lilly reported ObesityWeek 2026 data on Zepbound, Foundayo, EloraTZP and retatrutide, including weight-loss and cardiometabolic results and signals in sleep apnea, psoriatic arthritis and knee osteoarthritis. EloraTZP Phase 2 data showed up to 23.3% weight loss. The findings add evidence across related conditions, while approval, safety, tolerability, manufacturing, pricing and supply remain execution risks.
Lilly signs oncology collaboration with Stipple Bio worth up to $5.9 billion
Stipple Bio entered a multi-target oncology research and licensing collaboration with Eli Lilly. Stipple will use its Pointillist Platform to identify tumor-specific cell-surface binders, while Lilly applies its oncology technologies to develop therapies across multiple modalities. Lilly receives exclusive worldwide development and commercialization rights to resulting products, and Stipple may earn up to $5.9 billion in milestone payments plus tiered royalties.
Lilly makes Zepbound and Foundayo available through Hims & Hers
Eli Lilly partnered with Hims & Hers to offer eligible patients prescribed Zepbound and Foundayo through its digital platform, with consultations, delivery and ongoing weight-management support. The service expands Lilly’s direct-to-consumer access channels, and Hims says it will not offer compounded copies of Lilly’s medicines. The partnership’s financial contribution will depend on patient uptake and deal economics.
Eli Lilly’s retatrutide delivered greater A1C reductions and weight loss than the highest approved Ozempic dose in a Phase 3 trial, strengthening Lilly’s position in the GLP-1 market. Its pipeline also includes eloralintide and oral weight-loss drug Foundayo, while expanding uses for tirzepatide could support future growth. New approvals and commercial success remain uncertain.
China approves Lilly’s oral weight-loss drug orforglipron
China approved Eli Lilly’s oral weight-loss drug orforglipron, giving it an early lead over Novo Nordisk’s oral Wegovy, which was still awaiting approval. Lilly is preparing a launch through authorized healthcare and pharmaceutical institutions but has not disclosed pricing. The articles describe a large and growing Chinese obesity-treatment market, while noting competition and uncertainty around pricing, reimbursement and launch speed.
Foundayo reduces sleep apnea severity in Phase 3 trial
Lilly reported Phase 3 ATTAIN-OSA results showing once-daily Foundayo reduced apnea-hypopnea events after 52 weeks by 43.8% in participants not using PAP therapy and 27.5% in those using it. Up to 31.5% of non-PAP participants achieved remission or mild OSA. The drug also reduced hypoxic burden, body weight, inflammation and systolic blood pressure; gastrointestinal effects were common.
Lilly breaks ground on $3.5 billion Pennsylvania manufacturing site
Eli Lilly broke ground on a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, expected to open by 2031. The site will produce injectable medicines, including investigational obesity drug retatrutide, and is part of Lilly’s $50 billion U.S. manufacturing expansion. It is expected to create 850 permanent jobs and about 2,000 construction jobs.
Lilly reports one-year results for Taltz and Zepbound combination
Lilly reported 52-week Phase 3b TOGETHER-PsA results showing Taltz plus Zepbound maintained or improved disease, patient-reported and metabolic outcomes versus Taltz alone in adults with psoriatic arthritis and obesity or overweight. At Week 52, 43.7% on the combination achieved ACR50, compared with 15.7% on Taltz alone; 39.2% achieved both ACR50 and at least 10% weight loss, versus 1.7%.
Fauna Bio designates second obesity target under Lilly collaboration
Fauna Bio designated a second obesity drug-discovery target from a different tissue under its collaboration with Eli Lilly, triggering an undisclosed milestone payment. The multi-year collaboration, launched in December 2023, uses Fauna’s comparative-genomics and AI platforms to identify obesity targets and offers Fauna up to $494 million in milestone payments plus royalties.
Bank of America raises Lilly price target to $1,557
Bank of America raised its Eli Lilly price target to $1,557 from $1,497, maintaining a Buy rating and citing Lilly’s growth and execution. Ahead of its Dec. 7 Innovation Day, analyst Jason Gerberry highlighted five non-obesity pipeline programs, including candidates for narcolepsy, depression, breast cancer and Alzheimer’s. The programs’ potential depends on trial success.
Lilly reports 48% revenue growth as GLP-1 demand accelerates
Liontrust GF Global Dividend Fund’s Q3 2026 letter highlighted Eli Lilly, which reported revenue growth of 48% year over year to $23 billion and raised full-year revenue guidance to $85 billion–$87 billion, reflecting continued GLP-1 demand. The fund returned -0.6% for the quarter but remained ahead of its benchmark year to date.
Eli Lilly May Have Just Found a New $23 Billion Market for Its GLP-1 Pill
Eli Lilly’s Foundayo sales rose from $98 million in Q2 to $184 million in Q3, and its Phase 3 sleep apnea trial success could add a new indication, with an FDA submission planned by the end of 2026. Lilly is also pursuing diabetes approval and international launches, while retatrutide and expanded Medicare access offer further growth opportunities. Jefferies raised its price target to $1,700, though the consensus target implies about 6% upside. Analysts forecast 42% EPS growth in 2027. A $1,800 share price would require a 31% gain and a valuation of 36 times 2027 earnings, with pricing pressure and nonrecurring costs among the risks.
Lilly highlights retatrutide, Zepbound and Taltz data at ACR meeting
Eli Lilly highlighted retatrutide, Zepbound and Taltz data at the 2026 American College of Rheumatology meeting. The article also discussed the company’s share price and a valuation estimate, noting risks including reliance on obesity drugs, pricing pressure and possible adverse safety data.
Eli Lilly secures changes to advertising for compounded tirzepatide
Eli Lilly secured changes to a competitor’s advertising for compounded tirzepatide products after raising safety and marketing concerns. The company said it sought to protect patients and its branded GLP-1 franchise. The article also described Lilly’s pipeline reshaping through acquisitions, divestments and discontinued programs, with priorities including oncology, immunology and gene therapy.
LifeMD will let eligible patients with prescriptions from its affiliated providers buy Lilly’s Zepbound and Foundayo at Lilly’s self-pay prices. Dispensing and nationwide shipment will be handled through LifeMD’s licensed mail-order pharmacy. The cash-pay program is not billed to insurance and requires an independent clinical evaluation. The companies may explore adding other medicines.